2022 Alzheimer’s Disease Facts and Figures Report; experts available
3-Mar-2022 11:05 AM EST
Add to Favorites
3-Mar-2022 11:05 AM EST
Add to Favorites
Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.
28-Jul-2021 8:05 AM EDT
Add to Favorites
On behalf of all those living with Alzheimer's disease, their caregivers, and their families, we appreciate the Centers for Medicare & Medicaid Services (CMS) thoughtful consideration on coverage considerations for monoclonal antibodies targeting...
13-Jul-2021 8:45 AM EDT
Add to Favorites
Aduhelm has been approved for use for those with Mild Cognitive Impairment or early stage Alzheimer's dementia. This treatment offers a marginal but potentially meaningful slowing of decline for this subpopulation of individuals with Alzheimer's...
12-Jul-2021 8:45 AM EDT
Add to Favorites
The Alzheimer's Association is pleased with the announcement today that the Food and Drug Administration (FDA) has revised the prescribing label for Aduhelm™ (aducanumab).
8-Jul-2021 6:00 PM EDT
Add to Favorites
As the global nonprofit leader in Alzheimer's research and science we have extensively reviewed the clinical trial data for Aduhelm™ (aducanumab).
14-Jun-2021 8:05 AM EDT
Add to Favorites
A simple blood test for Alzheimer’s would be a great advance for individuals with — and at risk for — the disease, families, doctors and researchers.
27-Jul-2020 9:05 AM EDT
Add to Favorites
- Report provides latest Alzheimer’s prevalence, incidence, mortality and costs of care data -
- Barring medical breakthroughs, the number of people age 65+ with Alzheimer’s dementia may nearly triple by 2050 -
11-Mar-2020 8:00 AM EDT
Add to Favorites
7-Jun-2021 12:20 PM EDT
2-Jun-2021 3:45 PM EDT
26-Mar-2020 4:45 PM EDT
The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.